Skip to content

Regulation of Fat-stimulated Neurotensin Secretion in Healthy Subjects

Mechanistic Study (Physiology)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00541762
Enrollment
34
Registered
2007-10-10
Start date
2006-01-31
Completion date
2007-03-31
Last updated
2015-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Neurotensin, Human, Physiology of neurotensin, fat perfusion, healthy subjects

Brief summary

Context: Cholecystokinin (CCK) and neurotensin are stimulated during meal intake by the presence of fat in the small intestine. The sequence of events suggests that fat hydrolysis is crucial for triggering the release. Objectives: The aim of this study was therefore to investigate whether CCK mediated the effect of intraduodenal (ID) fat on neurotensin secretion via CCK-1 receptors.

Detailed description

Setting: Single center study; 34 male volunteers were studied in consecutive, randomized, double blind, crossover studies. Subjects and Methods: CCK and neurotensin release were quantified in: 1) 12 subjects receiving an ID fat infusion with or without 60 mg orlistat, an irreversible inhibitor of gastrointestinal lipases, in comparison to vehicle. 2) 12 subjects receiving ID long chain fatty acids (LCF), ID medium chain fatty acids (MCF) or ID vehicle. 3) 10 subjects receiving ID LCF with and without the CCK-1 receptor antagonist dexloxiglumide (DEXLOX) or ID vehicle plus IV saline (placebo). Hormone concentrations were measured by specific RIA systems.

Interventions

DIETARY_SUPPLEMENTFat perfusion to the small intestine

1. Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine 2. Orlistat perfused to the small intestine 3. DEXLOX as CCK-1 receptor antagonist

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy male subjects

Design outcomes

Primary

MeasureTime frame
Neurotensin plasma concentrationsChange in plasma cocnentrations over 2-3 hours

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026